Cleanroom floor and wall solutions from Sika meet rigorous standards for pharmaceutical manufacturing facilities.
Sika
A new service from Sika, a manufacturer of pharmaceutical floor and wall systems, will enable life sciences companies to assert greater control over the design, construction, maintenance, and cost of existing and new facilities. The company is making its network of technical, design, and construction experts available to architects, designers, and managers of pharmaceutical facilities to create systems that address the unique demands of pharma environments. Working along with Sika’s installation partners, companies can benefit from time-and cost-saving installation technology.
In applications for cleanrooms and other areas requiring the most stringent environmental monitoring, Sika has developed a hygienic envelope system that integrates floors, walls and ceilings into a seamless, non-porous, chemical-resistant barrier. This technique facilitates the ease and speed of sanitization and prevents liquids from compromising the substrate which could create the possibility of back-side mold growth.
“Controlled spaces in biologics, pharmaceutical, medical device, and clean production facilities are subject to both local and global inspections against rigorous standards,” said Jim Hendley, Life Sciences Vertical Market Manager, Sika Corporation USA, in a press release. “At Sika, we believe it is essential to integrate the designer, manufacturer and facility manager in to a team, to understand these issues and provide a holistic, no-surprise, flooring and-importantly-full-envelope system that maintain performance expectations, sterility, and construction schedules.”
This approach ensures the facility owner has greater control over the performance of the system through its lifetime and prevents failures. Sika systems offer durability and longevity, with chemical, mechanical, and impact resistance.
Source: Sika
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.